Page 9 - Sohini Das

Automakers gear up to roll out EVs without rare earth magnets by FY27

While companies remain tight-lipped about the development, most acknowledge that such a transition is essential to align with the rapid growth of the EV sector

Pharma body seeks rethink on entry curbs of MRs in govt hospitals

Indian Pharmaceutical Alliance warns that the DGHS ban on medical representatives may affect public health, slow innovation and result in pharma sector job losses

Renalyx launches smart dialysis unit RxT21, plans ₹800 crore boost

Renalyx Health Systems launches AI-enabled dialysis machine RxT21 with real-time monitoring at ₹6.7 lakh, plans to scale production and expand into global markets

TaMo eyes 40% CV, 16% PV market share; EV biz hits Ebitda breakeven

Tata Motors targets 40% share in CVs and 16% in PVs by FY27, plans major EV investments and demerger of vehicle businesses by end-2025

AC norms bring chills to truck segment; to pinch pockets by up to 2%

Truck sales dipped in May 2025 as AC cabins became mandatory for all new medium and heavy vehicles, with OEMs backing the rule and fleet owners flagging cost and workforce concerns

From showrooms to shelves, India likely to witness consumption uptick

Godrej Consumer Products also expects demand to rise for categories like personal care and home care

Rare earth crisis: Indian companies hopeful as global panic sets in

With China tightening rare earth exports, Indian firms eye domestic incentives and stockpiling, as global automakers and medical device makers face rising supply fears

Wockhardt's novel antibiotic Zaynich eyes $9 billion global market

Company to launch Zaynich in India this fiscal; sees $7 bn market in US and EU and ₹17,000 crore in India; USFDA, EU filings underway for FY26

Bangladesh unrest cuts India's medical tourism revenue by up to 35%

India sees sharp fall in Bangladeshi medical tourists in FY25 as regime change and visa curbs hurt Apollo and Manipal revenues; recovery expected only by FY26

Harrier.ev in driver's seat as Tata Motors eyes 50% market share in EVs

Electric PV market expected to grow by over 50% in FY26; company yet to disclose full price range of Harrier EV

Tata Motors bets on Altroz to 2x market share in premium hatchbacks

The 25,000-30,000 units a month premium hatchback segment accounts for nearly 6-7 per cent of passenger vehicle (PV) sales, and is dominated by models like Baleno of Maruti Suzuki

Bharat Biotech's oral cholera vaccine Hillchol clears phase 3 trials

In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years

Entry-level car buyers priced out even as SUV sales surge in India

Two-wheeler owners finding upward mobility challenging

Torrent Pharma Q4 PAT up 11% on strong India biz; Aman Mehta named MD

Torrent Pharma posts Rs 498 crore PAT in Q4FY25; Aman Mehta to become MD from August 1 as part of long-term strategic succession planning by the board

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Passenger vehicles sales up 4% in April, two-wheeler despatches fall

Overall exports up 20% in April amid geopolitical tensions, says SIAM

Piramal Pharma expects single-digit growth in FY26 amid uncertainties

PPL projects a muted FY26 due to global headwinds but aims to double its India consumer health business turnover to Rs 2,000 crore by FY30 through scale and expansion

Tata Motors Q4FY25 profit drops 51%, flags challenges amid tariff war

Deferred tax gain and exceptional costs dent Q4 profit for Tata Motors, though FY25 revenue and PBT hit record highs amid global challenges and tariff uncertainties

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

IPA and Ind-Ra say Trump's MFN-based drug pricing move will impact innovators more than Indian generics, with CDMO firms likely to gain from offshore cost advantages

US President Donald Trump's drug price slash could sting Indian pharma

Up to 80% US price cuts may squeeze margins, push up innovator drug costs